# Retevmo (selpercatinib) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/selpercatinib

> The FDA approved Retevmo (selpercatinib), sponsored by ELI LILLY & Co (LLY), on April 10, 2024.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Retevmo (selpercatinib) |
| Codes | LY3527723, LOXO-292 |
| Sponsor | ELI LILLY & Co (LLY) https://sec-api.dev/companies/lly/catalysts |
| Indications | [Carcinoma, Non-Small-Cell Lung](https://sec-api.dev/indications/carcinoma-non-small-cell-lung) |
| Modality |  |
| FDA designations | priority review |

## Timeline

### May 8, 2020: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA213246 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20200508, review_priority PRIORITY; sponsor_name ELI LILLY AND CO; product RETEVMO (SELPERCATINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213246%22

### September 21, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA213246 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20220921, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product RETEVMO (SELPERCATINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213246%22
- openFDA Drugs@FDA: "NDA213246 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20220921, review_priority PRIORITY; sponsor_name ELI LILLY AND CO; product RETEVMO (SELPERCATINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213246%22

### April 10, 2024: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA218160 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20240410, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product RETEVMO (SELPERCATINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218160%22

### May 29, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA213246 SUPPL-12 (Efficacy): submission_status AP, submission_status_date 20240529, review_priority PRIORITY; sponsor_name ELI LILLY AND CO; product RETEVMO (SELPERCATINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213246%22

### June 12, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA213246 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20240612, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product RETEVMO (SELPERCATINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213246%22
- openFDA Drugs@FDA: "NDA218160 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20240612, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product RETEVMO (SELPERCATINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218160%22

### September 27, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA213246 SUPPL-13 (Efficacy): submission_status AP, submission_status_date 20240927, review_priority PRIORITY; sponsor_name ELI LILLY AND CO; product RETEVMO (SELPERCATINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213246%22
- openFDA Drugs@FDA: "NDA213246 SUPPL-11 (Efficacy): submission_status AP, submission_status_date 20240927, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product RETEVMO (SELPERCATINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213246%22
- openFDA Drugs@FDA: "NDA218160 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20240927, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product RETEVMO (SELPERCATINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218160%22
- openFDA Drugs@FDA: "NDA218160 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20240927, review_priority PRIORITY; sponsor_name ELI LILLY AND CO; product RETEVMO (SELPERCATINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218160%22

### November 20, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA213246 SUPPL-15 (Efficacy): submission_status AP, submission_status_date 20251120, review_priority PRIORITY; sponsor_name ELI LILLY AND CO; product RETEVMO (SELPERCATINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213246%22
- openFDA Drugs@FDA: "NDA218160 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20251120, review_priority PRIORITY; sponsor_name ELI LILLY AND CO; product RETEVMO (SELPERCATINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218160%22

### January 12, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Carcinoma, Non-Small-Cell Lung.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04819100 (A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-01-12 (ACTUAL); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT04819100

### July 14, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA213246 SUPPL-17 (Efficacy): submission_status AP, submission_status_date 20260714, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product RETEVMO (SELPERCATINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213246%22
- openFDA Drugs@FDA: "NDA218160 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20260714, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product RETEVMO (SELPERCATINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218160%22

## Same indication

- [6-thio-2'-deoxyguanosine](https://sec-api.dev/pdufa/6-thio-2-deoxyguanosine) (MAIA)
- [Krazati (adagrasib)](https://sec-api.dev/pdufa/adagrasib) (BMY)
- [Disitamab vedotin](https://sec-api.dev/pdufa/disitamab-vedotin) (PFE)
- [JNJ-90301900](https://sec-api.dev/pdufa/jnj-90301900) (JNJ)
- [Navlimetostat](https://sec-api.dev/pdufa/navlimetostat) (BMY)
- [Olomorasib](https://sec-api.dev/pdufa/olomorasib) (LLY)
- [Pembrolizumab/vibostolimab](https://sec-api.dev/pdufa/pembrolizumab-vibostolimab) (MRK)
- [Alimta (pemetrexed)](https://sec-api.dev/pdufa/pemetrexed) (LLY)
- [AUGTYRO (repotrectinib)](https://sec-api.dev/pdufa/repotrectinib) (BMY)
- [Sigvotatug vedotin](https://sec-api.dev/pdufa/sigvotatug-vedotin) (PFE)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/selpercatinib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Retevmo (selpercatinib) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/selpercatinib

```bibtex
@misc{secapidev_pdufa_selpercatinib_20261116,
  title        = {Retevmo (selpercatinib) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/selpercatinib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_selpercatinib_20261116","title":"Retevmo (selpercatinib) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/selpercatinib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
